ReviewMedical oncology (Northwood, London, England)2017
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The Research Progress of Neurotrophic Tyrosine Receptor KinaseIranian journal of public health · 2025Review
- RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Current treatment options in oncology · 2023Review
- FFPE-Based NGS Approaches into Clinical Practice: The Limits of Glory from a Pathologist Viewpoint.Journal of personalized medicine · 2022Review
- A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy.Annals of translational medicine · 2022Article
- Role of novel cancer gene SLITRK3 to activate NTRK3 in squamous cell lung cancer.Molecular biomedicine · 2021Article
- Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.NPJ precision oncology · 2021Article
- Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.Current treatment options in oncology · 2021Review
- Non-Small-Cell Lung Cancer: New Rare Targets-New Targeted Therapies-State of The Art and Future Directions.Cancers · 2021Review
- Molecular Testing on Cytology for Gene Fusion Detection.Frontiers in medicine · 2021Review
- TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer.Journal of Cancer · 2021Article
- Review
- Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review.Translational lung cancer research · 2020Review
- Immunocytochemistry of cytology specimens for predictive biomarkers in lung cancer.Translational lung cancer research · 2020Review
- Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.Molecular diagnosis & therapy · 2020Article
- Validity of patient-derived xenograft mouse models for lung cancer based on exome sequencing data.Genomics & informatics · 2020Article
- Xiaoai Jiedu Recipe Inhibits Proliferation and Metastasis of Non-Small Cell Lung Cancer Cells by Blocking the P38 Mitogen-Activated Protein Kinase (MAPK) Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Antitumor activity of larotrectinib in tumors harboringOncoTargets and therapy · 2019Article
- Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing.Frontiers in pharmacology · 2019Review
- Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.Genome medicine · 2018Article
- Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?Journal of clinical medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK rearrangements represent the molecular driver of a subset of solid tumors, including 3% of non-small-cell lung cancers (NSCLCs). Preliminary data indicate that molecularly selected NSCLC patients harboring NTRK fusions derive an unprecedented clinical benefit from Trk-directed targeted therapies. The aim of this review is to describe the molecular biology of NTRK signaling pathway and to summarize the preclinical data on novel Trk inhibitors, touching upon the clinical development of these inhibitors for the treatment of advanced NSCLC, which have already shown encouraging anticancer activity and acceptable safety profile in early phase I clinical trials.
Indexed as
Identifiers
28444624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.